SC 13G/A: Galmed Pharmaceuticals Ltd.
Ticker: GLMD · Form: SC 13G/A · Filed: Sep 20, 2024 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | SC 13G/A |
| Filed Date | Sep 20, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by Galmed Pharmaceuticals Ltd..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G/A filing submitted by Galmed Pharmaceuticals LTD. (ticker: GLMD) to the SEC on Sep 20, 2024.
What is the risk level of this SC 13G/A filing?
This filing has been assessed as low risk.
How long is this filing?
Galmed Pharmaceuticals LTD.'s SC 13G/A filing is 3 pages with approximately 921 words. Estimated reading time is 4 minutes.
Where can I view the full SC 13G/A filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 921 words · 4 min read · ~3 pages · Grade level 9.8 · Accepted 2024-09-20 14:18:08
Filing Documents
- y920242sc13ga1.htm (SC 13G/A) — 37KB
- 0001214659-24-016590.txt ( ) — 38KB
(a)
Item 1(a). Name of Issuer: Galmed Pharmaceuticials Ltd.
(b)
Item 1(b). Address of Issuer's Principal Executive Offices: 16 Tiomkin Street, Tel Aviv, Israel, 6578317
(a)
Item 2(a). Name of Person Filing: MASAYA OTSUKA
(b)
Item 2(b). Address of Principal Business Office or, if none, Residence: Yukarigaoka Miyanodai Haitsu #314 1-3-1 Miyanodai, Sakura-shi,Chiba-ken,285-0857, JAPAN
(c)
Item 2(c). Citizenship: JAPAN
(d)
Item 2(d). Title of Class of Securities: Ordinary Shares
(e)
Item 2(e). CUSIP Number: M47238122 Page 3 of 6 Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ¨ Broker or dealer registered under Section 15 of the Act; (b) ¨ Bank as defined in Section 3(a)(6) of the Act; (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act; (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940; (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E) ; (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F) ; (g) ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G) ; (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; (j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J) ; (k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K) . If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 0 (b) Percent of Class: 0% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 0 Page 4 of 6 Item 5. If this statement is being filed to report the fact that as of the date hereof the